Intravitreal bevacizumab (Avastin) injection in ocular ischemic syndrome.
OBJECTIVE
To determine whether bevacizumab may improve anatomic and visual outcomes in patients with ocular ischemic syndrome (OIS).


METHODS
Interventional case reports.


METHODS
Two patients with OIS presenting with unilateral ocular pain, iris neovascularization, and macular edema. Intravitreal injection of bevacizumab (1.25 mg). The main outcome measures were postinjection best-corrected visual acuity (BCVA), intraocular pressure (IOP), angiographic findings, and optical coherence tomography (OCT) findings and complications.


RESULTS
One week after treatment, both patients demonstrated regression of the iris neovascularization and improvement of the macular edema, with no changes in BCVA and IOP. One eye was reinjected at four months. After three and seven months, no significant or systemic adverse events were observed, and no signs of new iris neovascularization were present.


CONCLUSIONS
Intravitreal bevacizumab may be useful for the treatment of eyes with iris neovascularization and macular edema secondary to OIS.
Amselem
Luis
L
Department of Ophthalmology, Mayo Clinic, Rochester, Minnesota, USA.
Montero
Javier
J
Diaz-Llopis
Manuel
M
Pulido
Jose S
JS
Bakri
Sophie J
SJ
Palomares
Paula
P
Garcia-Delpech
Salvador
S
D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D005451:Fluorescein Angiography; D006801:Humans; D007267:Injections; D007429:Intraocular Pressure; D007498:Iris / Q000098:blood supply*; D007511:Ischemia / Q000150:complications / Q000188:drug therapy*; D008269:Macular Edema / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D008297:Male; D009389:Neovascularization, Pathologic / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D013577:Syndrome; D041623:Tomography, Optical Coherence; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity; D014822:Vitreous Body
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab